Health officials, researchers and patients are locked in a debate over whether blockbuster GLP-1 drugs such as Ozempic can trigger gastroparesis, the condition often nicknamed “stomach paralysis.” Fresh analyses and mounting patient reports have turned up the volume, leading regulators and drugmakers to underscore that most people tolerate the medications well even as researchers scrutinize rare but serious digestive problems. The stakes are high, since millions of Americans now use these drugs for diabetes or weight loss and the trade-offs touch both health and everyday life.
What the studies found
An analysis from the University of British Columbia that examined roughly 16 million U.S. insurance records found that people taking semaglutide or liraglutide for weight loss had about a 3.67 times higher risk of receiving a gastroparesis diagnosis compared with patients prescribed bupropion-naltrexone. The researchers and outside experts emphasize that this reflects relative risk from observational claims data and that the actual number of cases was small. Broader safety reviews point out that nausea and vomiting are common effects across the GLP-1 class, while evidence about very rare, severe gastrointestinal events is still taking shape, according to a recent review in the Journal of Clinical Investigation.
How GLP-1s slow the gut
GLP-1 receptor agonists work in part by mimicking a natural gut hormone that slows how quickly the stomach empties. That slowdown helps curb appetite but also explains why many patients feel queasy, a side effect that is clearly flagged in product labeling. The FDA’s prescriber information for semaglutide notes that the drug can delay gastric emptying, which may change how other medications are absorbed and, in rare instances, contribute to severe gastrointestinal reactions. The details are spelled out in the FDA label.
Small clinical studies suggest the delay can be striking at the start. In one trial of liraglutide, the median time for the stomach to half empty was around 4 minutes with placebo versus about 70 minutes on the drug after five weeks, with some patients taking up to 151 minutes. By 16 weeks, the median half-emptying time dropped to roughly 30 minutes, according to reporting in the Sacramento Bee that summarized the research literature.
Regulators and drugmakers respond
The FDA has told reporters that it has received reports of gastroparesis and related intestinal issues in people using GLP-1 medicines, but the agency notes that voluntary case reports on their own cannot prove the drugs caused the problems, according to CBS News. Regulators have also said that, for many patients, the benefits of these medications may still outweigh the potential risks…